The endogenous double-stranded RNA (dsRNA) virus Leishmaniavirus (LRV1) has been implicated as a pathogenicity factor for leishmaniasis in rodent models and human disease, and associated with drug-treatment failures in Leishmania braziliensis and Leishmania guyanensis infections. Thus, methods targeting LRV1 could have therapeutic benefit. Here we screened a panel of antivirals for parasite and LRV1 inhibition, focusing on nucleoside analogs to capitalize on the highly active salvage pathways of Leishmania, which are purine auxotrophs. Applying a capsid flow cytometry assay, we identified two 2′-C-methyladenosine analogs showing selective inhibition of LRV1. Treatment resulted in loss of LRV1 with first-order kinetics, as expected for random virus segregation, and elimination within six cell doublings, consistent with a measured LRV1 copy number of about 15. Viral loss was specific to antiviral nucleoside treatment and not induced by growth inhibitors, in contrast to fungal dsRNA viruses. Comparisons of drug-treated LRV1
+ and LRV1 − lines recapitulated LRV1-dependent pathology and parasite replication in mouse infections, and cytokine secretion in macrophage infections. Agents targeting Totiviridae have not been described previously, nor are there many examples of inhibitors acting against dsRNA viruses more generally. The compounds identified here provide a key proof-ofprinciple in support of further studies identifying efficacious antivirals for use in in vivo studies of LRV1-mediated virulence.
trypanosomatid protozoan parasite | endobiont virus | viral segregation | chemotherapy | virulence P rotozoan parasites of the genus Leishmania are responsible for leishmaniasis in many regions of the world, with 12 million current cases (accompanied by at least 10-fold more bearing asymptomatic infections) and nearly 1.7 billion people at risk (1) (2) (3) (4) (5) . The disease has three predominant clinical manifestations, ranging from the relatively mild, self-healing cutaneous form, to mucocutaneous lesions where parasites metastasize to and cause destruction of mucous membranes of the nose, mouth, and throat, or fatal visceral disease. Disease phenotypes segregate primarily with the infecting species; however, it is not fully understood which parasite factors affect severity and disease manifestations.
One recently identified parasite factor contributing to disease severity in several Leishmania species is the RNA virus Leishmaniavirus (6, 7). These endobiont viruses classified within the Totiviridae are comprised of a single-segmented double-stranded RNA (dsRNA) genome that encodes only a capsid protein and an RNA-dependent RNA polymerase (RDRP) (8, 9) . Leishmaniavirus is most frequently found in New World parasite species in the subgenus Viannia [as Leishmania RNA virus 1 (LRV1)], such as Leishmania braziliensis (Lbr) and Leishmania guyanensis (Lgy), which cause both cutaneous and mucocutaneous disease (6) , and is found sporadically in Old World subgenus Leishmania species [as Leishmania RNA virus 2 (LRV2)] (10, 11) . Mice infected with LRV1-bearing strains of L. guyanensis exhibit greater footpad swelling and higher parasite numbers than mice infected with LRV1 − L. guyanensis (7) . Similarly, macrophages infected in vitro with LRV1 + L. guyanensis or LRV2 + Leishmania aethiopica release higher levels of cytokines, which are dependent on Toll-like receptor 3 (7, 10) . Recently, methods for systematically eliminating LRV1 by RNA interference have been developed, enabling the generation of isogenic LRV1 − lines and allowing the extension of the LRV1-dependent virulence paradigm to L. braziliensis (12) .
A key question is the relevancy of the studies carried out in murine models to human disease. For L. guyanensis, patients infected with LRV1
+ strains show an increased severity of cutaneous disease (13) . In humans, L. braziliensis is associated with cutaneous leishmaniasis, as well as the larger share of the more debilitating mucocutaneous leishmaniasis (MCL). Thus far there are no data available in humans permitting tests of the association of LRV1 with L. braziliensis parasite burden nor the severity of cutaneous leishmaniasis (CL), which can show a range of presentations (14, 15) . In lieu of such information, studies have focused on the association of LRV1 with MCL vs. CL, which is thought to reflect primarily immunopathology rather than parasite numbers (2, 6, (14) (15) (16) . Although in some studies LRV1 was not correlated with MCL clinical manifestations (17, 18) , in others there was a strong association (6, 19, 20) . The basis for these discrepancies is of considerable interest, hypotheses for which include other parasite or host factors known to play a significant role in the development of MCL (13, 21, 22) , or
Significance
The endogenous double-stranded RNA virus Leishmaniavirus (LRV1) has been implicated as a pathogenicity factor for leishmaniasis in rodent models and human disease, and associated with drug-treatment failures. As a first step toward the identification of therapeutic LRV1 inhibitors, we identified two adenosine analogs that selectively inhibited LRV1 replication. These analogs were used as tools to confirm that viral inheritance is by random segregation, as well as to generate LRV1-cured lines of Leishmania guyanensis, which correspondingly lost the increased pathogenicity conferred by LRV1. These compounds hold promise as leads to ameliorate the severity of LRV1-bearing Leishmania infections, and raise the possibility of targeting other protozoal infections whose pathogenicity may be exacerbated by similar endogenous viruses.
microbial sources including the microbiota or coinfections (23) . Recent studies show that the presence of LRV1 in clinical isolates of L. braziliensis and L. guyanensis correlates with drug-treatment failure (17, 20) , phenomena that could readily be explained by the increased parasite numbers or altered host responses predicted from animal models (7, 13, 24) . Thus, current data support a role for LRV1 in increasing disease severity in human leishmaniasis (13) ; this suggests that therapies targeting LRV1 specifically could be applied toward amelioration of disease pathology. As one approach, murine vaccination using the LRV1 capsid results in significant protection against LRV1 + L. guyanensis (25) . Here we describe a complementary approach, targeting LRV1 directly using small-molecule inhibitors. Although effective antivirals are available for many viral targets including retroviruses, DNA viruses, and single-strand RNA (ssRNA) viruses (26) , little effort has gone into agents acting against dsRNA viruses (27) . These comprise at least 10 viral families (Birnaviridae, Botybirndaviridae, Chrysoviridae, Cystoviridae, Megabirnavirdae, Partitiviridae, Picobirnaviridae, Quadriviridae, Reoviridae, and Totiviridae), infecting a wide array of hosts, including fungi, plants, and animals (28) . Some constitute important agricultural pathogens and rotaviruses (Reoviridae) cause serious human disease. For protozoan viruses, their role in the exacerbation of human disease is only now beginning to be appreciated (6, 29) . Because viral elements are critical factors acting to exacerbate the disease where studied, candidate anti-LRV1 agents should be viewed as "antipathogenicity" treatments rather than sterilizing cures (30) , which could be used alone or more likely in combination with existing antileishmanial agents in the treatment of ongoing infection.
As a starting point, we focused on nucleoside analogs, a class that includes many widely used and effective antivirals (Table  S1 ) (26) . Following uptake and activation to the triphosphate form, these analogs primarily target viral replication, with different classes acting preferentially against viral DNA or RNA polymerases (RDRP) or reverse transcriptases, as well as cellular metabolism. A second rationale was that Leishmania are purine auxotrophs, with highly active and multiply redundant pathways for uptake and activation of nucleobases and nucleosides (31) . Indeed, a great deal of prior effort has been devoted to the development of antileishmanial purine analogs; however, whereas the nucleobase allopurinol is commonly used as a veterinary agent, it has proven more difficult to find agents of sufficient potency and selectivity against Leishmania to be used widely against human leishmaniasis (32) . We reasoned that the highly divergent properties of Totiviridae RDRPs, relative to the polymerases of both the Leishmania and mammalian hosts (as well as other viral RDRPs), could prove fertile grounds for antiviral discovery, especially when coupled with potentiation by the parasite's powerful nucleoside/base salvage pathways.
Results
Measurement of LRV1 Levels by Capsid Flow Cytometry. Because LRV1 (like most Totiviridae) is not shed from the cell (33, 34), we developed a flow cytometric assay to measure intracellular LRV1 capsid levels on a per cell basis. To detect LRV1 we used binding to a rabbit anti-LgyLRV1 capsid antiserum (35) followed by detection with Alexa Fluor488-conjugated goat anti-rabbit IgG. We found that fixation with 2% (wt/vol) paraformaldehyde followed by permeabilization with Triton X-100 yielded a clear LRV1-dependent profile (Fig. 1A) . Titration of the anticapsid antiserum showed that dilutions around 1:16,000 gave a strong signal with excellent selectivity between LgyLRV1 + and LRV1 − (Fig. 1B) , with little background staining evident in immunofluorescence microscopy. Under these conditions and as seen in previous immunofluorescence studies (36) , LgyLRV1 + showed a strong, homogeneous LRV1 distribution (Fig. 1A) . We attempted similar studies with anti-dsRNA antibodies (36), but were unable to identify fixation conditions that gave similarly clear discrimination between LgyLRV1 + and LRV1 − by flow cytometry.
Inhibition Tests. We acquired a collection of 81 compounds, primarily nucleoside or nucleobase analogs, including ones shown previously to be active against diverse viruses, tumor cells, or Leishmania ( Fig. S1 and Tables S1 and S2). These compounds were examined for their ability to inhibit the growth of LgyLRV1 + and virus levels by LRV1 capsid flow cytometry. LgyLRV1 − parasites grew similarly to LgyLRV1 + and were used as virus-negative controls. These data revealed three patterns (Fig. 2) . For most compounds, LRV1 capsid levels were not significantly affected, within a factor of ∼3 (Fig. 2 , black or red dots within large dashed gray and red circles, Fig. S2 , and Table S2 ). All nucleobase analogs fell within this group, as did foscarnet (a structure analog of pyrophosphate). Within this group, a subset showed more than 10-fold inhibition of L. guyanensis growth (Fig. 2 , red dashed circle and black dots above; Fig. S3 A and B; and Table S2) , including known antileishmanials, such as allopurinol, mycophenolic acid, and 4-aminopyrazolopyrimidine (APP). Several additional compounds showed leishmanial inhibition at the concentration tested (Fig. 2, Fig. S2B , and Table S2 ); however, these were deprioritized for various reasons, including known mammalian cell toxicity. In the initial screens several compounds showed modest elevation of LRV1, often accompanied by growth inhibition (Fig. 2, Fig. S2A , and Table S2 ). However, this effect was not always reproducible and was not pursued further. Two compounds strongly reduced LRV1 capsid levels with minimal impact on parasite growth ( Table S2 ). Both 2′-C-methyladenosine (2CMA) and 7-deaza-2′-C-methyladenosine (7d2CMA) resulted in 12-fold reductions in LRV1 capsid levels, showing 30% and 90% inhibition of parasite density, respectively, when tested at 100 μM. Both had previously been shown to inhibit the hepatitis C virus (HCV) RDRP following activation (37, 38) . In contrast, 2′-C-methylcytidine or guanosine had little effect on LRV1 levels or L. guyanensis growth (Fig. 2 , blue dots). Compounds bearing a variety of other 2′ modifications (alone or in combination, with various bases) showed little effect on LRV1. These included sofosbuvir and mericitabine (related to 2′-C-methyl-2′-F uridine or cytidine, respectively), both of which show strong activity against HCV (39, 40) , or NITD008, which shows good activity against flaviviruses (41) . These data suggest a strong preference for both the nature of the 2′-C substitution, as well as adenine as the base. Note that these data cannot discriminate between effects arising from direct inhibition of RDRP or other viral processes, nor drug metabolism (phosphorylation or resistance to nucleoside hydrolases).
Previously, a Leishmania cysteine proteinase activity was implicated in the cleavage of the LRV1 capsid-RDRP fusion protein, potentially important for LRV1 biogenesis (42) . However, no effects on L. guyanensis growth and only minimal effects on LRV1 capsid levels were observed with three cysteine proteinase inhibitors tested (E64, E64d, and CA-074) (Table S2) , relative to the effects of 2CMA or 7d2CMA.
2CMA Preferentially Inhibits LRV1 Replication. Titrations were performed to quantitate the potency of 2CMA and 7d2CMA against L. guyanensis growth and LRV1, measuring the relative cellular growth rate to better assess fitness effects. For 2CMA, the EC 50 was estimated to be ∼3 μM for LRV1 capsid inhibition, versus >100 μM for parasite growth (Fig. 3A) , at least 30-fold selective. To assess the effects on replication of the dsRNA LRV1 genome directly, we used quantitative anti-dsRNA slot blots (Fig. 3A) (36), which showed an EC 50 of ∼1 μM, slightly less than seen with capsid inhibition and consistent with the anticipated targeting of the RDRP. With 7d2CMA, an EC 50 of ∼5 μM was seen against LRV1 capsid expression, versus ∼ >100 μM for L. guyanensis growth, again with about >20-fold selectivity (Fig. 3B ). Several studies were carried out with L. braziliensis strains bearing LRV1 (12) . The 2CMA EC 50 for LbrLRV1 was similar to that seen with LgyLRV1 (∼3 μM); however, parasites were somewhat more susceptible to growth in inhibition (EC 50 50-100 μM). Because the available quantities of 7d2CMA were limiting and both compounds were similarly selective for L. guyanensis, we focused thereafter on 2CMA.
Inhibition of 2CMA LRV1 Is Unaffected by Exogenous Adenine, nor Is Synergy Seen with Antileishmanial Nucleobases. We asked whether the 2CMA potency was affected by the presence of exogenous adenine, present at about 5-33 μM in the yeast extract component of Schneider's medium (43) . The addition of adenine up to 400 μM had no impact on LRV1 inhibition by 100 μM 2CMA, nor did it alter LRV1 levels in LgyLRV1 + (Fig. S3C ). APP showed similar inhibition of L. guyanensis growth and LRV1 levels, whereas at the highest concentration tested, allopurinol inhibited L. guyanensis growth or LRV1 capsid levels by 30 or 60%, respectively (Fig. S3A ). We then explored potential interactions between 2CMA and antileishmanial nucleobases. However, no change in the EC 50 for 2CMA inhibition of L. guyanensis growth or LRV1 capsid synthesis was seen with increasing concentrations of allopurinol (∼3 μM) (Fig. S3D) . Table S2 plotted; LRV1 capsid levels (y axis) vs. L. guyanensis growth (x axis). The large dashed gray circle marks compounds (black dots) showing little effect on LRV1 or L. guyanensis, the red circle marks compounds preferentially inhibiting L. guyanensis growth, and the green circle marks compounds preferentially inhibiting LRV1; blue dots depict 2′C substituted nucleosides without anti-LRV1 activity. LgyLRV1 + and
LgyLRV1
− controls are shown in brown. Abbreviations for compounds discussed further in the text can be found in Table S1 . LRV1 Inhibition Is Independent of Leishmania Growth Inhibition.
Agents inducing stress or growth arrest have been used to cure fungal Totiviridae, with cycloheximide (CHX) used often (44, 45) . Growth of L. guyanensis at 10 or 100 nM CHX resulted in an increase in population doubling time, from ∼7.7 h to 11.2 or 44.7 h, respectively, without significant cell death as evidenced by resumption of WT growth following CHX removal (Fig. 4A) . Despite the strong effects on growth, LRV1 capsid levels were unaffected, nor was the emergence of a "LRV1 − " parasite population seen at any CHX concentration (Figs. 4 B and C) . Similar results were obtained with clotrimazole, which inhibits Leishmania growth through inhibition of sterol synthesis (Fig. 4D) . Finally, no correlation was seen between LRV1 levels and growth rate in our test compound screening (Fig. 2 and Fig. S2 ) or exposure to hygromycin B (46) . Thus, inhibition of Leishmania growth alone does not alter LRV1 levels.
Viral Loss Occurs by Random Dilution. The availability of an inhibitor with strong selectivity for LRV1 over parasite growth provided an opportunity to test the assumption that cytosolic Totiviruses are passed randomly to daughter cells during mitosis (34, 47) . For maximal LRV1 inhibition, parasites were inoculated into 100 μM 2CMA, which increased the population doubling time from 6.4 to 8.5 h (Fig. 3) . The average LRV1 levels immediately declined, with capsid and RNA levels falling in parallel ( Fig. 5 A and B) . Importantly, when plotted as a function of number of cell divisions, loss of LRV1 capsid and RNA followed a first-order linear relationship, with a 50% loss at every doubling ( Fig. 5 A and B) . When visualized at the population level by flow cytometry, LRV1 capsid levels per cell declined homogeneously at every time point tested until only background staining was evident by six cell doublings (Fig. 5C ). Both of these observations closely match the expectation for the random distribution of LRV1 particles to daughter cells during mitosis and successive cell divisions.
2CMA Induces LRV1
− Populations. To explore the loss of LRV1 further, we performed a series of "washout" experiments, growing LgyLRV1 + in 100 μM 2CMA for one, three, four, or six cell doublings followed by transfer to drug-free media. After one doubling, a time when LRV1 levels had only decreased twofold, LRV1 capsid levels rapidly returned to WT levels and distribution. In contrast, when 2CMA was maintained for three or four cell doublings, resulting in a homogeneous population showing on average 8-or 16-fold less LRV1 capsid expression, the washout lines now showed two distinct populations (Fig. 5 C and D) . One population expressed LRV1 at levels similar to control LgyLRV1 + , whereas the other resembled LgyLRV1 − (Fig. 5D , Top and Middle). Parasites with LgyLRV1 + capsid levels were the majority (55%) in the three-doubling washout population, whereas these had declined to 36% percent in the four-doubling washout population (Fig. 5D) . The LgyLRV1 − population increased from 31 to 50% of the total cell population during this time. Finally, after six cell doublings of growth with 2CMA, the LRV1 capsid profile was indistinguishable from that of the LgyLRV1 − and the six-doubling washout population revealed only parasites maintaining the LgyLRV1 − capsid-staining profile (Fig. 5D ). This population was maintained for at least six passages (∼40 cell doublings) without return of any demonstrable LRV1 + parasites. Several conclusions emerge from these studies: first, the effective LRV1 copy number per cell must be relatively low, as otherwise an LRV1
− population could not emerge after only three to six cell doublings (Fig. 5) , roughly corresponding to copy numbers of 8-64 (2 3 − 2 6 ) and consistent with fraction of LRV1 − cells emerging in the washouts (Fig. 5D ). LgyLRV1 copy number was previously estimated as 24-100 by competitive PCR assay (48) . To assess LRV1 copy number independently in the clonal LgyLRV1 + line studied here, we isolated total RNA quantitatively from a known number of cells, and estimated LRV1 copy number by quantitative RT-PCR (qRT-PCR), using a standard curve established from a cloned LRV1 genome (Methods). This process yielded an estimated average LRV1 copy number of 15 ± 0.9 per cell (n = 3), consistent with range estimated from the rate of drug-induced loss above.
Second, after washout, 2CMA-treated parasites, which originally showed homogeneous low levels of LRV1, now reverted to biphasic populations showing WT or "negative" LRV1 levels. The recovery of the WT-like population suggests that there may be a "set point" for LRV1 levels. Because only populations but not clones were studied, we cannot be sure that this occurred intracellularly; however, the rapidity with which LRV1 levels rebounded suggests this may be more likely.
Rapid Recovery of Matched Clonal WT and LRV1-Cured Lines. Our findings suggested that it should be relatively easy to recover LRV1 − clonal lines from the 2CMA-treated population. However, we were concerned that despite small effects on growth, the relatively high concentration of 2CMA used above could itself have unwanted selective effects on L. guyanensis. Support for this concern arose when in pilot studies, several clonal lines obtained after growth in 100 μM 2CMA lacked LRV1 but showed decreased growth inhibition by 2CMA. Thus, we repeated the LRV1 cure using 10 μM 2CMA, a concentration showing less of an effect on parasite growth but retaining strong inhibition of LRV1 levels (Fig. 3) . Again, loss of LRV1 proceeded homogeneously (Fig. 6A) . When clonal lines were recovered directly by plating from this population, very few were LRV1 − (1 of 30). However, if the population was allowed to grow in the absence of 2CMA for another ∼six cell doublings (washout), a bimodal population for LRV1 capsid levels emerged, as seen previously. Analysis of 12 clonal lines obtained by direct plating from this washout population showed that six exhibited LRV1 capsid levels/profiles identical to the LgyLRV1 − control, whereas two showed profiles identical to the LgyLRV1 + parent (representatives shown in Fig. 6B ). Interestingly, four lines showed more complex profiles, with populations showing range of intensities spanning those from LRV1 − to LRV1 + controls (representative shown in Fig. 6B ). These complex lines were not studied further. The set-point hypothesis predicts that upon further growth, those lines would ultimately revert to bimodal populations.
We chose two LRV1 + and LRV1-cured lines that had experienced identical 2CMA treatment and culture manipulations. Growth tests confirmed these were not resistant to 2CMA, and RT-PCR and Western blot tests confirmed the presence or absence of LRV1 (Fig. 6 C and D) . These clones thus constituted matched WT and LRV1-cured lines appropriate for subsequent studies of LRV1 effects.
LRV1 Correlates with Increased Cytokine Secretion and Mouse Infectivity.

With matched 2CMA-treated LRV1
+ and LRV1 − (cured) lines, we asked whether LRV1 was correlated with elevated pathology and hyperinflammatory responses, as expected (7, 12) . Infections were performed with bone marrow-derived macrophages (BMM) in vitro, followed by assays for secretion of two characteristic LRV1-dependent cytokine reporters, IL-6 and TNF-α. Cytokine secretion induced by the LRV1 + /2CMA-treated lines was comparable to that of the parental LgyLRV1 + line, whereas cytokine secretion induced by the 2CMA cured lines was considerably less, and comparable to that of the LgyLRV1 − control (Fig. 7 A and B) . Infections of susceptible BALB/c mice were performed followed by measurement of pathology (footpad swelling) and bioluminescent imaging of parasite numbers. A strong LRV1-dependency for both pathology and parasite abundance was observed in comparisons of the matched 2CMA-treated LRV1 + vs. LRV1 − (cured) lines (Fig. 7 C and D) . Importantly, the response to the 2CMA-treated LRV1 + lines closely matches that to the control parental LgyLRV1 + line and, similarly, the response to the 2CMA-treated LRV1 − line closely matches that to the LgyLRV1 − control (Fig. 7 C and D) , both of which were studied previously (7).
Discussion
In this study, we report the identification of compounds specifically targeting the LRV1 dsRNA virus of L. guyanensis and L. braziliensis, two representatives of the Totiviridae. Our findings have relevance for the specific therapeutic inhibition of Leishmaniavirus, basic studies of viruses within the Totiviridae, the development of antivirals directed against dsRNA viruses generally, and the development of new tools for assessing the role of LRV1 in elevating Leishmania pathogenicity.
To facilitate the search for LRV1 inhibitors, we first developed a capsid flow cytometry assay to rapidly monitor LRV1 capsid levels (Fig. 1) . This assay can be performed in only a few hours, and although these studies used it in a relatively low throughput manner, it should be scalable for higher throughput. The results were confirmed by anticapsid or anti-dsRNA Western or slot blotting, or quantitative RT-PCR (Fig. 6 C and D) . Additionally, this assay provides useful information about the cellular heterogeneity of LRV1 levels not readily achievable by other methods, which informed studies probing the inheritance of LRV1 as well as in the generation of LRV1 − lines. We focused on known antivirals for several reasons: first, despite significant advances in targeting many retroviruses, DNA viruses, or ssRNA viruses, very little effort or progress has been devoted on inhibition of dsRNA viruses. Thus, there seemed a reasonable potential for "repurposing" known antivirals against the dsRNA Leishmaniavirus. Moreover, because many antivirals are nucleoside analogs and that Leishmania is a purine auxotroph (31), the pharmacokinetics of drug uptake and metabolism could well favor the efficacy of such compounds against Leishmaniavirus. As a collateral benefit, these studies had the potential to uncover new lead inhibitors against Leishmania itself, as auxotrophy has prompted many investigators to target purine metabolism for antileishmanial therapy. Several new compounds not previously reported to inhibit Leishmania were identified ( Fig. 2 and Tables S1 and S2), but were not pursued further here.
We identified two compounds that showed preferential inhibition of LRV1, 2CMA, or 72CMA (Fig. 3 and Fig. S1 ). The two active compounds were effective in the micromolar range, with >20-fold selectivity for LRV1 versus L. guyanensis growth inhibition and were also active against LbrLRV1, albeit with somewhat less selectivity over growth. The EC 50 measured using dsRNA or capsid levels were similar, with that of the dsRNA being somewhat less, consistent with the anticipated mode of action targeting the RDRP and genome replication. Both compounds have demonstrated activity against HCV, where they target the viral RDRP by chain termination (37, 38, 49) . By molecular modeling of the L. guyanensis LRV1 RDRP domain against other RDRPs, such as HCV, we were able to generate a view of the active site including residues putatively binding to the nucleotide substrates (Fig. S4) . Notably, these included sites homologous to those mutated in HCV nucleoside analog-resistant lines (50) . This finding supports our working hypothesis that both anti-LRV1 compounds are activated to triphosphates, where they act to inhibit RDRP activity. These compounds represent the only inhibitors known to act against any member of the Totiviridae, and indeed some of the few candidates described inhibiting dsRNA viruses generally. Common features of the two selective anti-LRV1 compounds include the 2′-C methyl and the adenine base moieties, although 2′ C-methyl G and C were inactive against both Leishmania and LRV1. A similar pattern was observed for dengue virus RDRP inhibitors, where only adenosine analogs demonstrated antiviral activity (51) . Following uptake, in Leishmania most purine nucleosides are metabolized to nucleobases, the major exception being adenosine, which is phosphorylated directly by adenosine kinase (31) . This finding could contribute to the superiority of 2CMA analogs. However, all other 2′C-modified analogs tested failed to inhibit LRV1 or Leishmania, including ones bearing adenine or related moieties as the nucleobase (Fig. 2 and Tables S1 and S2).
Other factors may include differential ability to be phosphorylated, often the rate-limiting step for antiviral nucleoside activation (52, 53) , or susceptibility to nucleoside hydrolases or phosphorylases, which Leishmania possess in abundance (31) , and affinity of the phosphorylated analog with the LRV1 RDRP itself. Additional studies will be required to assess the contributions of each of these factors to anti-LRV1 activity and the design of more potent inhibitors.
Anti-LRV1 Agents as a Tool for Studying Leishmaniavirus Replication and Biology. The LRV1 selectivity of 2CMA and 7d2CMA provided the foundation for several studies probing LRV1 biology. Under 2CMA inhibition, a first-order kinetic loss of LRV1 was observed, (measured by either capsid or dsRNA genome levels), with a homogeneous 50% loss at every cell doubling (Fig. 5 A  and B) . This finding fits exactly the prediction assumed by a random-inheritance model of LRV1 particles during mitosis. Although widely assumed for the inheritance of most persistent dsRNA viral infections, these findings now provide direct evidence of random segregation. These data also provide a mechanistic explanation for the failure to identify compounds inhibiting both LRV1 and L. guyanensis in our screen, because without continued parasite growth LRV1 cannot be lost by dilution, and indeed may increase somewhat (Fig. 2) .
Ultimately, LRV1 levels declined to levels approaching those of LRV-free parasites within three to six cell doublings following 2CMA treatment (Fig. 5) . This finding implies the viral copy number was relatively low, less than 8-64 (2 [3] [4] [5] [6] ), significantly less than previous estimates of 120 for LgyLRV1 and often many thousands for other Totiviridae (34, 48) . However, quantitative analysis of cellular LRV1 and total RNA led to an estimate of about 15, consistent with estimates of LRV1 abundance from recent whole-genome RNA sequencing by our group. If this unexpectedly low value for LRV1 copy number applies generally to LRV1s in other Leishmania strains or species, it could provide a new perspective on the observation that thus far, no images of LRV1 in situ by electron microscopy appear in the literature. The rapid decline of LRV1 following 2CMA treatment suggested that it would be relatively easy to recover LRV1-free clonal lines. Following washout of 2CMA after three to six cell doublings and a brief period of growth without drug, cultures manifested two distinct parasite populations by capsid flow cytometry: one similar to LgyLRV1 + and a second similar to LgyLRV1 − (Figs. 5 and 6 ). The fraction of LgyLRV1 − parasites grew progressively with increasing 2CMA treatment, reaching levels approaching 100%. To recover parasites suited for studies focusing on the biological properties of LRV1 − parasites, we adopted a protocol in which parasites were treated for only a brief period with 10 μM 2CMA, a concentration showing little effect on parasite growth but relatively high inhibition of LRV1 (Fig. 3) , followed by brief passaging and then plating on drugfree media. Importantly, this procedure allowed the recovery of both LRV1
+ and LRV1 − matched clonal lines, which had experienced identical treatment, thereby facilitating comparisons probing LRV1 effects (below). Interestingly, in all of these studies the LRV1 levels in washout lines showed a strong tendency to recover from the low levels seen in drug to those comparable to LRV1
+ controls (Fig. 5 ). These findings suggest that the LRV1 copy number is maintained at a specific set point, perhaps through a balance between replication and the RNAi pathway (12, 54) . Previous studies examining LRV1 transcripts during growth phase also concluded that LRV1 copy number is regulated (48) .
For other fungal dsRNA viruses, treatments engendering cell stress or growth inhibition have been used to generate virus-free lines at significant frequencies, one common example being the use of CHX to cure the yeast L-A virus (44) . Although in one prior study LRV1 cure was obtained during a series of transfection and hygromycin selection steps, this appears to have been successful only once, and our laboratories have been unable to repeat this (12, 46) . Here we were unable to show any correlation between LRV1 loss and drug-induced stress or growth inhibition with CHX, the ergosterol synthesis inhibitor clotrimazole, or within the large panel of test compounds (Figs. 2 and 4, Fig. S2 , and Tables S1 and S2). Thus, LRV1 appears to be relatively stable to growth inhibitory stresses. However, given its relatively low cellular copy number (<20), on a strictly probabilistic basis LRV1 − variants might occur at a low frequency, which occasionally may emerge or be recovered by methods more sensitive than used here.
Antiviral Cures and the Generation of Isogenic LRV1
− Lines for the Study of LRV1-Dependent Virulence. Treatment with 2CMA enables the controlled and reproducible generation of matched LRV1 + and LRV1-cured lines without difficulty. In vivo, 2CMA-cured LRV1 − parasites showed less pathology and lower parasite numbers and induced less cytokine secretion than LRV1 + parasites, comparable to the single spontaneous LRV1
− lines described previously (Fig. 7) . Thus, our LRV1 toolkit now includes two independent, reproducible, and efficient methods for generating isogenic LRV1 − lines, which will facilitate tests probing the biology of LRV1-dependent pathogenicity in diverse parasite backgrounds. Depending on the relative selectivity of the antivirals and the presence of an RNAi pathway, one method may be superior for a given Leishmania species or strain.
The Potential for Antitotiviral Therapy in the Treatment of dsRNABearing Parasites and Disease. There are now ample data suggesting that LRV1 contributes to the severity in human leishmaniasis (6, 13, 17, 19, 20, 55) , suggesting that anti-LRV1 inhibitors could be clinically useful, alone or in conjunction with existing antileishmanials. Unfortunately, pharmacokinetic studies of the two compounds studied here in mammals suggest that neither of these are good candidates for testing of this hypothesis just yet, as the concentration needed for LRV1 elimination (10 μM) is above the maximum achievable serum concentration in various mammalian models, typically less than 1 μM (38, 49, 56) . Thus, future efforts must focus on the development of compounds with higher potency targeting LRV1, without significant human host toxicity. For therapeutic purposes a compound simultaneously targeting both would likely be superior. However, because Leishmania growth is required for LRV1 to be lost by progressive dilution (Fig. 5) , a screening method different from that used here will be required to detect such agents. Dilutional loss following anti-LRV1 inhibitor treatment in vitro predicts that very low levels of LRV1 could persist after treatment in vivo, whether measured on a total or per cell basis (Fig. 5) . Importantly, previous data show that below a certain threshold, parasites bearing low LRV1 levels are controlled as effectively as LRV1
− lines (7). Our studies also raise the possibility of treating other diseases caused by protozoans bearing dsRNA viruses, which show endogenous virus-dependent pathogenicity, including Totiviridae present within Trichomonas vaginalis (Trichomonasvirus), Giardia lamblia (Giardiavirus), or Eimeria (Eimeravirus) (34, 57) , and Partitiviridae within Cryptosporidium parvum (Cryspovirus) (58, 59) . Potentially, agents targeting these putative pathogenicity factor viruses could prove similarly valuable for laboratory studies of these viruses as well. Parasites were grown in Schneider's media (Sigma) prepared according to the supplier's instructions with pH adjusted to 6.5 and supplemented with 0.76 mM hemin, 2 μg/mL biopterin, 50 U/mL penicillin, 50 μg/mL streptomycin, and 10% (vol/vol) heat-inactivated FBS. Cell concentrations were determined using a Coulter Counter (Becton Dickinson).
Methods
Drug-Inhibition Tests. Compounds were purchased or obtained as summarized in Table S1 , and the structures of the two most active anti-LRV1 compounds are shown in Fig. S1 . Stock solutions were prepared as recommended by the source, typically in DMSO at 50 mM, and tested against parasites at 100 μM or the maximum concentration permitted by drug solubility (Table S2) . Parasites were inoculated at 2 × 10 5 cells/mL into Schneider's media lacking supplemental adenine. Growth was evaluated after 2 d, before the controls reached stationary phase growth, at which time parasite numbers had increased nearly 100-fold. Experiments were performed in sets of 10 test compounds, along with LRV1 + and negative controls; the agreement among independent experiments among the controls was excellent, and the results are shown averaged together across all experiments (Table S2) .
LRV1 Capsid Flow Cytometry. For capsid flow cytometry, 10 7 cells were fixed at room temperature using 2% (wt/vol) paraformaldehyde (Thermo Fisher) in PBS for 2 min. They were then incubated in blocking buffer [10% (vol/vol) normal goat serum (Vector Laboratories) and 0.2% Triton X-100 in PBS] for 30 min at room temperature. Anti-LgyLRV1 capsid antibody (35) was added (1:20,000 dilution) and incubated at room temperature for 1 h. After two washes with PBS, cells were resuspended in in 200 μL PBS with Alexa Fluor488-labeled goat anti-rabbit IgG (Alexafluor, Invitrogen; 1:1,000; or Thermo Fisher; 1:2,000 dilution), and incubated 1 h at room temperature. After two additional washes with PBS, cells were subjected to flow cytometry, gating for single cells using forward and side scatter and the data analyzed using CellQuest software (BD Bioscience).
RNA Purification, cDNA Preparation, and qRT-PCR. For RNA purification, 10 7 cells were resuspended in 350 μL TRIzol Reagent and RNA was extracted using the Direct-zol RNA purification kit according to protocol (Zymo Research). RNA was then treated with DNase I (Ambion) for 1 h at 37°C and repurified using RCC-5 column purification (Zymo Research). cDNA was prepared using SuperScript III (Invitrogen) and random priming according to protocol. RNA denaturation occurred at 65°C for 5 min. RT-PCR tests were performed using LRV1-specific primers (SMB4647 5′-TBRTWGCRCACAGTGAY-GAAGG and SMB4648 5′CWACCCARWACCABGGBGCCAT) or β-tubulin mRNA (SMB5023 5′-AACGCTATATAAGTATCAGTTTCTGTACTTTA and SMB2110 5′-GACAGATCTCATCAAGCACGGAGTCGATCAGC). qRT-PCR was performed as previously described (36) , with a 123-bp fragment of LRV1 capsid mRNA amplified with primers SMB5335 (5′-CTGACTGGACGGGGGGTAAT) and SMB5336 (5′-CAAAACACTCCCTTACGC), and a 100-bp fragment of KMP-11 (a Leishmania housekeeping gene) with primers SMB5548 (5′-GCCTGGATGAGGAGTTCAACA) and SMB5549 (5′-GTGCTCCTTCATCTCGGG). The reaction used Power SYBR Green (Applied Biosystems) in an ABI Prism 7000. Initial denaturation was at 95°C for 10 min followed by 40 cycles of amplification with 15 s at 95°C, and 1 min at 60°C. Data were analyzed using ABI 7000 SDS software (v1.2.3) and normalized using the ΔΔCT method (60) . RNA slot blot analysis was performed as described previously (36) . The LRV1 copy number per cell was estimated in comparison with a standard curve generated using DNA from a plasmid bearing the LRV1 capsid gene (B6760, pBSKLRV1-4) and the average yield of RNA per cell across multiple L. guyanensis RNA preparations (5.12 ± 1.17 μg/10 7 cells; n = 34).
Isolation of LRV1
+ and LRV1 − Clonal Lines by Brief Treatment with 2CMA.
LgyLRV1
+ parasites were grown for one passage in media containing 25 μg/mL nourseothricin (Werner BioAgent) to verify the presence of the integrated luciferase (LUC) gene (54) . Cells were then grown one passage in the absence of nourseothricin, and inoculated into Schneider's media at a concentration of 2 × 10 5 cells/mL into media containing 10 μM 2CMA. Growth was measured and LRV1 quantitated by capsid flow cytometry. At various times, cells were either plated directly, or transferred to drug-free media, and allowed to grow an additional six cell doublings before plating. For both, the semisolid M199 media contained 50 μg/mL nourseothricin, and cells were diluted so that no more than ∼100 colonies were obtained per plate.
Macrophage Infections, Cytokine Assays, and Mouse Infection. Infections of C57BL/6 mouse bone marrow-derived macrophages and cytokine assays were performed as previously described (7, 10) . Poly I:C was obtained from Invivogen and used at 2 μg/mL. For mouse infections, 5-to 6-wk-old C57BL/6 mice were purchased from Jackson Laboratories. Parasites were grown into stationary phase (2 full days) and 10 6 parasites were injected on the plantar aspect of the left foot. Measurement of footpad swelling was performed weekly using a Vernier caliper. Parasite numbers were assessed by luminescence of an integrated firefly luciferase reporter, measured using an IVIS 100 instrument as described previously (7, 54) 
